News

Study Finds Oral Microbiome Diversity Predicts Survival in Pancreatic Cancer Patients

Research Advances /

A clinical study (NCT06552078) examined how bacteria in the mouth and small intestine are linked to Pancreatic Ductal Adenocarcinoma (PDAC). To ensure accurate results, researchers excluded patients with bile duct blockages so that any microbial changes were related to the cancer itself, not secondary complications. The study included 24 PDAC patients and 24 healthy people […]

Study Finds Oral Microbiome Diversity Predicts Survival in Pancreatic Cancer Patients Read More »

Scientists Develop Dual-Action Nanotherapy That Completely Eliminates Tumors in Preclinical Study

Clinical Trails /

Researchers have developed a new nanomaterial that destroys cancer cells by triggering a dual chemical attack inside tumors. The study, published in Advanced Functional Materials, improves chemodynamic therapy (CDT). Unlike traditional CDT agents that produce only one harmful molecule, this iron-based material generates both hydroxyl radicals and singlet oxygen. These highly reactive molecules damage DNA

Scientists Develop Dual-Action Nanotherapy That Completely Eliminates Tumors in Preclinical Study Read More »

Scientists Develop “Caffebody” System That Uses Caffeine to Control Gene Editing and Immune Therapy

Technology Innovation /

Researchers have created a new system that uses caffeine to control gene editing and immune cell activity. The researchers designed a “Caffebody” platform that acts like a chemical switch, turning advanced treatments on and off using common substances. In this system, cells are engineered with three components: a caffeine-sensitive nanobody called a caffebody, a partner protein,

Scientists Develop “Caffebody” System That Uses Caffeine to Control Gene Editing and Immune Therapy Read More »

CYTOSHRINK Trial Finds No Added Benefit From SBRT in Advanced Kidney Cancer

Clinical Trails /

Results from the phase 2 CYTOSHRINK trial show that adding Stereotactic Body Radiation Therapy (SBRT) to the immunotherapy combination of nivolumab and ipilimumab does not improve outcomes for patients with newly diagnosed advanced renal cell carcinoma (RCC). In fact, progression-free survival was shorter in the SBRT group (6.3 months) compared with immunotherapy alone (10.2 months).

CYTOSHRINK Trial Finds No Added Benefit From SBRT in Advanced Kidney Cancer Read More »

Belzutifan Plus Pembrolizumab Reduces Recurrence Risk in High-Risk Kidney Cancer After Surgery

Drug Approvals /

Results from the phase 3 LITESPARK-022 trial show that adding belzutifan (Welireg) to pembrolizumab (Keytruda) significantly improves outcomes for patients with clear cell renal cell carcinoma (ccRCC) who are at high risk of recurrence after kidney removal surgery. The combination reduced the risk of cancer returning or death by 28% compared with pembrolizumab alone. At 30 months,

Belzutifan Plus Pembrolizumab Reduces Recurrence Risk in High-Risk Kidney Cancer After Surgery Read More »

Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Advanced Kidney Cancer Phase 3 Trial

Clinical Trails /

Results from the LITESPARK-011 Phase 3 trial show that the combination of belzutifan (Welireg) and lenvatinib (Lenvima) is more effective than cabozantinib (Cabometyx) for patients with advanced clear cell renal cell carcinoma (ccRCC) previously treated with immunotherapy. The combination improved progression-free survival to 14.8 months compared with 10.7 months for cabozantinib, reducing the risk of disease progression or

Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Advanced Kidney Cancer Phase 3 Trial Read More »

New “ABCs + D” Approach Brings Targeted Breakthroughs in Advanced Prostate Cancer

Clinical Trails /

Prostate cancer treatment has evolved from general hormone therapy to a personalized “ABCs + D” approach. While localized prostate cancer has a high 5-year survival rate, the focus is now on metastatic castration-resistant prostate cancer (mCRPC), which has historically had poor outcomes. Modern care emphasizes intensifying treatment earlier to achieve deeper responses. The “ABCs +

New “ABCs + D” Approach Brings Targeted Breakthroughs in Advanced Prostate Cancer Read More »

Gem-iDRS Fails to Outperform Standard Chemoradiotherapy in Muscle-Invasive Bladder Cancer

Clinical Trails /

The Phase 3 SunRISE-2 study tested a new bladder drug-delivery system, Gem-iDRS, combined with the immunotherapy drug cetrelimab, in patients with muscle-invasive bladder cancer (MIBC) who did not undergo bladder removal. Gem-iDRS releases chemotherapy directly into the bladder over several weeks, while the control group received standard chemoradiotherapy (CRT), which combines radiation with systemic chemotherapy.

Gem-iDRS Fails to Outperform Standard Chemoradiotherapy in Muscle-Invasive Bladder Cancer Read More »

CELMoDs Offer Powerful New Approach for Multiple Myeloma Treatment

Drug Approvals /

CELMoDs (Cereblon E3 Ligase Modulators) are a new generation of oral drugs for multiple myeloma that may replace older immunomodulatory drugs like lenalidomide and pomalidomide. Both types of drugs target the protein cereblon, but CELMoDs are more powerful. While older drugs mainly slow cancer cell growth, CELMoDs directly trigger cancer cell death. They more effectively

CELMoDs Offer Powerful New Approach for Multiple Myeloma Treatment Read More »

RETAIN Trials Support Bladder-Sparing Strategy in Muscle-Invasive Bladder Cancer

Clinical Trails /

The RETAIN-1 and RETAIN-2 trials studied a new “risk-adapted” approach for treating muscle-invasive bladder cancer (MIBC). Instead of automatically removing the bladder with radical cystectomy, researchers wanted to find out which patients could safely keep their bladder through careful monitoring. In this approach, patients first received chemotherapy (MVAC) combined with immunotherapy (nivolumab) before surgery. Their

RETAIN Trials Support Bladder-Sparing Strategy in Muscle-Invasive Bladder Cancer Read More »